CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 76 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2020. The put-call ratio across all filers is 0.27 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $625,092 | -30.7% | 18,423 | -26.6% | 0.00% | -33.3% |
| Q1 2023 | $902,522 | +7.8% | 25,084 | -15.8% | 0.00% | 0.0% |
| Q3 2022 | $837,000 | -88.7% | 29,780 | -89.1% | 0.00% | -87.5% |
| Q2 2022 | $7,377,000 | -5.4% | 273,620 | +19.5% | 0.02% | +4.3% |
| Q1 2022 | $7,798,000 | +4.2% | 228,948 | +18.2% | 0.02% | +43.8% |
| Q4 2021 | $7,482,000 | +117.0% | 193,641 | -1.6% | 0.02% | +60.0% |
| Q4 2020 | $3,448,000 | -40.4% | 196,792 | -49.5% | 0.01% | -52.4% |
| Q3 2020 | $5,783,000 | +239.4% | 389,942 | +197.5% | 0.02% | +162.5% |
| Q2 2020 | $1,704,000 | +1752.2% | 131,094 | +282.1% | 0.01% | – |
| Q2 2019 | $92,000 | – | 34,308 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |